Literature DB >> 15521358

Signaling mechanisms of the D3 dopamine receptor.

Joy A Ahlgren-Beckendorf1, Beth Levant.   

Abstract

A substantial body of evidence shows the capacity of the dopamine D3 receptor to couple functionally to G proteins when expressed in an appropriate milieu in heterologous expression systems. In these systems, activation of D3 receptors inhibits adenylate cyclase, modulates ion flow through potassium and calcium channels, and activates kinases, most notably mitogen-activated protein kinase. Coupling to Gi/Go is implicated in many of these effects, but other G proteins may contribute. Studies with chimeric receptors implicate the third intracellular loop in the mediation of agonist-induced signal transduction. Finally, D3-preferring drugs modulate expression of c-fos in neuronal cultures and brain. Signaling mechanisms of the D3 receptor in brain, however, remain to be definitively determined.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15521358     DOI: 10.1081/rrs-200029953

Source DB:  PubMed          Journal:  J Recept Signal Transduct Res        ISSN: 1079-9893            Impact factor:   2.092


  11 in total

1.  Molecular characterization of individual D3 dopamine receptor-expressing cells isolated from multiple brain regions of a novel mouse model.

Authors:  Ying Li; Eldo V Kuzhikandathil
Journal:  Brain Struct Funct       Date:  2012-01-29       Impact factor: 3.270

2.  Effects of risperidone on dopamine receptor subtypes in developing rat brain.

Authors:  Taylor Moran-Gates; Christopher Grady; Young Shik Park; Ross J Baldessarini; Frank I Tarazi
Journal:  Eur Neuropsychopharmacol       Date:  2006-12-18       Impact factor: 4.600

3.  The tetrahydroisoquinoline derivative SB269,652 is an allosteric antagonist at dopamine D3 and D2 receptors.

Authors:  Elena Silvano; Mark J Millan; Clotilde Mannoury la Cour; Yang Han; Lihua Duan; Suzy A Griffin; Robert R Luedtke; Gabriella Aloisi; Mario Rossi; Francesca Zazzeroni; Jonathan A Javitch; Roberto Maggio
Journal:  Mol Pharmacol       Date:  2010-08-11       Impact factor: 4.436

4.  Identification and characterization of a novel class of atypical dopamine receptor agonists.

Authors:  E V Kuzhikandathil; S Kortagere
Journal:  Pharm Res       Date:  2012-05-01       Impact factor: 4.200

5.  Differential regional and dose-related effects of asenapine on dopamine receptor subtypes.

Authors:  Frank I Tarazi; Taylor Moran-Gates; Erik H F Wong; Brian Henry; Mohammed Shahid
Journal:  Psychopharmacology (Berl)       Date:  2008-02-24       Impact factor: 4.530

6.  Activity-dependent modulation of limbic dopamine D3 receptors by CaMKII.

Authors:  Xian-Yu Liu; Li-Min Mao; Guo-Chi Zhang; Christopher J Papasian; Eugene E Fibuch; Hong-Xiang Lan; Hui-Fang Zhou; Ming Xu; John Q Wang
Journal:  Neuron       Date:  2009-02-12       Impact factor: 17.173

7.  The neurosteroidogenic enzyme 5α-reductase modulates the role of D1 dopamine receptors in rat sensorimotor gating.

Authors:  Roberto Frau; Laura J Mosher; Valentina Bini; Giuliano Pillolla; Romina Pes; Pierluigi Saba; Silvia Fanni; Paola Devoto; Marco Bortolato
Journal:  Psychoneuroendocrinology       Date:  2015-09-24       Impact factor: 4.905

8.  Identifying Medication Targets for Psychostimulant Addiction: Unraveling the Dopamine D3 Receptor Hypothesis.

Authors:  Thomas M Keck; William S John; Paul W Czoty; Michael A Nader; Amy Hauck Newman
Journal:  J Med Chem       Date:  2015-03-31       Impact factor: 7.446

9.  Characterization of ST14A Cells for Studying Modulation of Voltage-Gated Calcium Channels.

Authors:  Mandy L Roberts-Crowley; Ann R Rittenhouse
Journal:  PLoS One       Date:  2015-07-06       Impact factor: 3.240

10.  Decreased Caffeine-Induced Locomotor Activity via Microinjection of CART Peptide into the Nucleus Accumbens Is Linked to Inhibition of the pCaMKIIa-D3R Interaction.

Authors:  Qiang Fu; Xiaoyan Zhou; Yun Dong; Yonghong Huang; Jianhua Yang; Ki-Wan Oh; Zhenzhen Hu
Journal:  PLoS One       Date:  2016-07-12       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.